Latest Updates

Stay up on the latest exciting news and updates from the Defeat GBM Research Collaborative.

Publications based on Defeat GBM research findings:

  1. Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS. (2014) Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med. 11: 255-263.
    file:///Users/akingston/Desktop/823-1967-2-PB.pdf
  2. Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL. (2014) Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene. 34(31): 4078-88
    http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2014336a.html
  3. Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY. (2014) EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest.124: 3741-3756.
    http://www.jci.org/articles/view/73093/version/2/pdf/render
  4. Masui K, Cavenee WK, Mischel PS. (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab. 25: 364-373.
    http://www.sciencedirect.com/science/article/pii/S1043276014000721
  5. Vivanco I, Chen ZC, Tanos B, Oldrini B, Hsieh WY, Yannuzzi N, Campos C, Mellinghoff IK. (2014) A kinase-independent function of AKT promotes cancer cell survival. Elife. 3. doi: 10.7554/eLife.03751. [Epub]
    http://elifesciences.org/content/elife/3/e03751.full.pdf
  6. Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB. (2015) A Urokinase Receptor-Bim Signaling Axis Emerges During EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma. Cancer Res. 75: 394-404.
    http://cancerres.aacrjournals.org/content/75/2/394.abstract
  7. Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, Mischel PS, Kohmura E. (2015) Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest. 125:1591-1602
    http://www.jci.org/articles/view/78239/version/2/pdf/render
  8. Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. (2015) Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. (2015) Nat Rev Cancer. 15: 302-310. doi: 10.1038/nrc3918.
    http://www.nature.com/nrc/journal/v15/n5/pdf/nrc3918.pdf
  9. Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavanee WK, Mischel PS. (2015) Glucose-dependent acetylation of Rictor  promotes targeted cancer therapy resistance. Proc Natl Acad Sci. 112: 9406-11.
    http://www.pnas.org/cgi/doi/10.1073/pnas.1511759112
  10. Nichol D, Mellinghoff IK. (2015) PI3K pathway inhibition in GBM—is there a signal? Neuro Oncol. doi: 10.1093/neuonc/nov124. [Epub ahead of print].
    http://neuro-oncology.oxfordjournals.org/content/early/2015/07/12/neuonc.nov124.full.pdf+html
  11. Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, Barr CL, Furnari FB, Cloughesy TF, Yong WH, Gahman TC, Shiau AK, Cavenee WK, Ren B, Mischel PS. (2015) EGFR mutation promotes glioblastoma through epigenome and transcription factor network remodeling. Mol Cell. 60: 307-318.
    http://www.cell.com/molecular-cell/pdf/S1097-2765(15)00698-X.pdf